Get notified when QURE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsuniQure plans UK regulatory filing for Huntington's gene therapy AMT-130 in Q3 2026
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
uniQure held pre-submission meeting with UK drug regulator (MHRA) for AMT-130, its experimental gene therapy for Huntington's disease, and plans to file Marketing Authorization Application in Q3 2026—a key step toward potential commercialization.
Item 8.01 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade QURE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 16, 2026 3:42 PM